Clinical Case Reports (Jan 2022)
Sequential allogeneic transplantation and ruxolitinib maintenance for a synchronous PCM1‐JAK2 positive myeloid sarcoma and acute B‐lymphoblastic leukemia
- Giuliana Rizzuto,
- Matteo Leoncin,
- Silvia Imbergamo,
- Daniela Taurino,
- Maria Caterina Mico,
- Manuela Tosi,
- Anna Michelato,
- Ksenija Buklijas,
- Orietta Spinelli,
- Federico Lussana,
- Federica Lessi,
- Marco Pizzi,
- Laura Bonaldi,
- Gianni Binotto,
- Alessandro Rambaldi,
- Carmela Gurrieri
Affiliations
- Giuliana Rizzuto
- Hematology and Bone Marrow Transplantation Unit Azienda Socio‐Sanitaria Territoriale Papa Giovanni XXIII Bergamo Italy
- Matteo Leoncin
- Hematology and Clinical Immunology Unit Universita` degli Studi di Padova Padua Italy
- Silvia Imbergamo
- Hematology and Clinical Immunology Unit Universita` degli Studi di Padova Padua Italy
- Daniela Taurino
- Hematology and Bone Marrow Transplantation Unit Azienda Socio‐Sanitaria Territoriale Papa Giovanni XXIII Bergamo Italy
- Maria Caterina Mico
- Hematology and Bone Marrow Transplantation Unit Azienda Socio‐Sanitaria Territoriale Papa Giovanni XXIII Bergamo Italy
- Manuela Tosi
- Hematology and Bone Marrow Transplantation Unit Azienda Socio‐Sanitaria Territoriale Papa Giovanni XXIII Bergamo Italy
- Anna Michelato
- Hematology and Bone Marrow Transplantation Unit Azienda Socio‐Sanitaria Territoriale Papa Giovanni XXIII Bergamo Italy
- Ksenija Buklijas
- Hematology and Bone Marrow Transplantation Unit Azienda Socio‐Sanitaria Territoriale Papa Giovanni XXIII Bergamo Italy
- Orietta Spinelli
- Hematology and Bone Marrow Transplantation Unit Azienda Socio‐Sanitaria Territoriale Papa Giovanni XXIII Bergamo Italy
- Federico Lussana
- Hematology and Bone Marrow Transplantation Unit Azienda Socio‐Sanitaria Territoriale Papa Giovanni XXIII Bergamo Italy
- Federica Lessi
- Hematology and Clinical Immunology Unit Universita` degli Studi di Padova Padua Italy
- Marco Pizzi
- Department of Pathology Università degli Studi di Padova Padua Italy
- Laura Bonaldi
- Oncological Immunology and Molecular DiagnosticIstituto Oncologico Veneto Padua Italy
- Gianni Binotto
- Hematology and Clinical Immunology Unit Universita` degli Studi di Padova Padua Italy
- Alessandro Rambaldi
- Hematology and Bone Marrow Transplantation Unit Azienda Socio‐Sanitaria Territoriale Papa Giovanni XXIII Bergamo Italy
- Carmela Gurrieri
- Hematology and Clinical Immunology Unit Universita` degli Studi di Padova Padua Italy
- DOI
- https://doi.org/10.1002/ccr3.5212
- Journal volume & issue
-
Vol. 10,
no. 1
pp. n/a – n/a
Abstract
Abstract The translocation t(8;9)(p22;p24) results in the production of a chimeric PCM1‐JAK2 fusion protein leading to the constitutive activation of the Janus Kinase 2 that renders this disease potentially sensitive to ruxolitinib. Here, we report an interesting case of PCM1‐JAK2 myeloproliferative neoplasm evolving in myeloid sarcoma and B precursor ALL.
Keywords
- acute B‐lymphoblastic leukemia
- case report
- myeloid sarcoma
- PCM1‐JAK2 myeloproliferative neoplasm
- ruxolitinib
